Skip to main content
. 2023 Jun 4;30(6):5456–5469. doi: 10.3390/curroncol30060413

Figure 3.

Figure 3

Subgroup analysis comparing overall survival between patients in the sequential treatment and in the non-sequential treatment with trifluridine/tipiracil and regorafenib groups stratified by baseline characteristics. Abbreviations: HR, hazard ratio; PS, performance status; T, trifluridine/tipiracil, R, regorafenib; mets, metastases; wt, wild type; mt, mutant type; 95% CI, 95% confidence interval; yrs, years.